论文部分内容阅读
目的 :安络化纤丸联合恩替卡韦对慢性乙型肝炎病毒(HBV)感染者病毒复制及肝纤维化指标、Th1/Th2细胞因子的影响。方法 :207例纳入研究的慢性HBV感染病例随机分为观察组(107例)和对照组(100例),两组依据病理类型再分为慢性乙型肝炎(CHB)、乙肝肝硬化两个亚组。对照组在常规治疗的基础上给予恩替卡韦,观察组在对照组的基础上给予安络化纤丸。治疗3个月,观察两组乙肝病毒脱氧核糖核酸(HBV-DNA)载量及肝纤维化指标[透明质酸(HA)、层粘连蛋白(LN)、Ⅳ型胶原(Ⅳ-C)、Ⅲ型前胶原肽(PⅢP)]、Th1/Th2细胞因子[白介素-2(IL-2)、白介素-10(IL-10)、白介素-4(IL-4)及干扰素-γ(IFN-γ)]水平。结果 :(1)治疗后,两组各亚组HBV-DNA拷贝数的绝对数均明显下降(P<0.05),且观察组各亚组的下降幅度均大于对照组的同名亚组(P<0.05);(2)治疗后,两组各亚组的LN、HA、Ⅳ-C、PⅢP均明显下降(P<0.05),且观察组各亚组LN、HA、Ⅳ-C、PⅢP的下降幅度大于对照组的同名亚组(P<0.05);(3)治疗后,两组各亚组的IL-2、IFN-γ明显上升而IL-4、IL-10明显下降(P<0.05),且观察组各亚组IL-2、IFN-γ、IL-4、IL-10的变化幅度均大于对照组同名亚组(P<0.05)。结论:安络化纤丸联合恩替卡韦用于慢性HBV感染能更有效的抑制乙肝病毒复制,且抑制肝纤维化及调节免疫的作用更显著,优于单用恩替卡韦。
Objective: To investigate the effect of Anglutix Pills combined with entecavir on viral replication, hepatic fibrosis and Th1 / Th2 cytokines in patients with chronic hepatitis B virus infection. Methods: A total of 207 cases of chronic HBV infection were randomly divided into observation group (n = 107) and control group (n = 100). The two groups were divided into two groups: chronic hepatitis B (CHB) and hepatitis B cirrhosis group. The control group was given entecavir on the basis of routine treatment. The observation group was given Anluo Huaxiang Wan on the basis of the control group. After 3 months of treatment, the levels of hepatitis B virus DNA (HBV-DNA) and liver fibrosis indicators (HA, LN, IV-C, Type procollagen peptide (PⅢP)], Th1 / Th2 cytokines [interleukin-2 (IL-2), interleukin- 10 (IL-10), interleukin- 4 (IL-4) and interferon-γ )]Level. Results: (1) After treatment, the absolute number of copies of HBV-DNA in each subgroup significantly decreased (P <0.05), and the decrease in each subgroup of the observation group was greater than that in the control group (P < 0.05). (2) After treatment, LN, HA, Ⅳ-C and PⅢP in each subgroup decreased significantly (P <0.05), and the levels of LN, HA, Ⅳ-C and PⅢP decreased (3) After treatment, the levels of IL-2 and IFN-γ in each subgroup were significantly increased and the levels of IL-4 and IL-10 were significantly decreased in both subgroups (P <0.05) , And the changes of IL-2, IFN-γ, IL-4 and IL-10 in the subgroups of the observation group were all greater than those of the same name subgroup in the control group (P <0.05). Conclusion: Anluhuanyuan pill combined with entecavir for chronic HBV infection can inhibit hepatitis B virus replication more effectively, and the effect of inhibiting liver fibrosis and regulating immunity is more significant than using entecavir alone.